This economic evaluation assesses the health economic value, for a US Medicare payer, of adopting perioperative enfortumab vedotin plus pembrolizumab for treatment of cisplatin-ineligible patients with muscle-invasive bladder cancer.
Z. Su, Tyler S. Garman, Carlos A. Rivera López et al.· JAMA Network Open· 0 citations
Background The Open Payments program (OPP) was launched in 2013 following the passage of the Physician Payments Sunshine Act (PPSA) to promote transparency of physician-industry financial relationships. Extensive research has scrutinized general (non-research) payments from industry to physicians. However, industry-spo...
Z. Su, Z. Hammadeh, Logan B. Galansky et al.· PLoS ONE· 0 citations
BACKGROUND
The association between alcohol consumption and prostate cancer (PCa) outcomes remains mixed, with particularly limited data on the association between alcohol consumption and risk of upgrading among men undergoing active surveillance (AS).
METHODS
We analyzed men with Grade Group (GG) 1 PCa managed in a p...
Jack A. Campbell, Michelle I. Higgins, Z. Su et al.· The Prostate· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.